Severe Mitral Insufficiency Following Mitral Valvotomy

Original title: Acute Severe Mitral Regurgitation Following Balloon Mitral Valvulotomy: Echocardiographic Feature, Operative Finfing and Outcome in 50 Surgical Cases. Reference: Manjunath C. Nanjappa, et al. Catherization and Cardiovascular Intervention 81:603-608 (2013)

Severe Mitral Insufficiency Following Mitral Valvotomy (VPM) is a major complication; though not frequent, (0.9%-2%) it is life threatening and requires resolution through valve replacement.

The aim of this series was to analyze the evolution of patients with acute severe mitral insufficiency following VPM. 3855 patients undergoing VPM were analyzed, 50 patients (1.3%) presented ASMR after procedure and where referred to surgery. Wilkins score was ≤8 in 23 of those 50 patients. The most frequent signs of ASMR were hypotension and hypoxia followed by orthopnea and acute pulmonary edema.

The most frequent cause of severe MR was posterior mitral leaflet tear (36 patients), it was also observe a paracommisural tear with annular involvement (7 patients), posterior mitral leaflet tear (5 patients) and chordal tear (2ptes). The time from end of procedure to replacement surgery was between 3 and 96 hrs, and 6 patients died in this period (12%).

Patients were analyzed according to the moment of surgery and were divided in 2 groups: 24 hrs (11 patients). Both groups shared similar characteristics, mortality being significantly higher in the second group (1/39 vs 5/11, p<0.001).

Conclusion: 

Hypotension and hypoxia were the most common symptoms of Severe Mitral Insufficiency Following Mitral Valvotomy and posterior mitral leaflet tear was the most frequent cause. In this scenario, early valve replacement is most recommended.

Editorial comment: 

Mitral Valvotomy is a complex procedure that presents a low complications rate but these can be severe. Clinical, hemodynamic evaluation, with eco-Doppler is essential seeing that they not only help evaluate results, they also help diagnose complications and make the correct and timely decisions. 

Courtesy of Dr. Carlos Fava.
Interventional Cardiologist.
Favaloro Foundation. Argentina.

 

Dr. Carlos Fava para SOLACI.ORG

More articles by this author

Contemporary Challenges in Left Atrial Appendage Closure: Updated Approach to Device Embolization

Even though percutaneous left atrial appendage (LAA) closure is generally safe, device embolization – with 0 to 1.5% global incidence – is still a...

Cardiac Remodeling After Percutaneous ASD Closure: Should It Be Immediate or Progressive?

Atrial septal defect (ASD) is a common congenital heart disease that generates a left-to-right shunt, leading to right-side chamber overload and a risk of...

Is it really necessary to monitor all patients after TAVR?

Conduction disorders (CD) after transcatheter aortic valve replacement (TAVR) are a frequent complication and may lead to the need for permanent pacemaker implantation (PPI)....

Is it really necessary to monitor all patients after TAVR?

Conduction disorders (CD) after transcatheter aortic valve replacement (TAVR) are a frequent complication and may lead to the need for permanent pacemaker implantation (PPI)....

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

COILSEAL: Use of Coils in Percutaneous Coronary Intervention, Useful for Complication Management?

The use of coils as vascular closing tool has been steadily expanding beyond its traditional role in neuroradiology into coronary territory, where it remains...

Treatment of In-Stent Restenosis in Small Vessels with Paclitaxel-Coated Balloons

Coronary artery disease (CAD) in smaller epicardial vessels occurs in 30% to 67% of patients undergoing percutaneous coronary intervention and poses particular technical challenges....

Contemporary Challenges in Left Atrial Appendage Closure: Updated Approach to Device Embolization

Even though percutaneous left atrial appendage (LAA) closure is generally safe, device embolization – with 0 to 1.5% global incidence – is still a...